Gaziantep University (GAÜN) Rector Prof. Dr. Ali Gür announced that with the collaboration of Gaziantep University’s Farmagen Clinical Research Center and Novagenix Bioanalytical Drug R&D Center, a study has begun to develop local and national equivalents (alternatives) of drugs imported from abroad for use in COVID-19 treatment. Rector Prof. Dr. Ali Gür emphasized that the clinical bioequivalence study of this drug will be conducted by Farmagen, one of the GAÜN Technopark companies, and shared the following details: "The active ingredient in question is currently used effectively in the treatment of COVID-19, which has been declared a pandemic by our Ministry of Health and the World Health Organization. Our studies on bioavailability and bioequivalence have started under the approval of the Ministry of Health's Turkish Medicines and Medical Devices Agency. These studies are carried out by a wide project team led by Project Responsible GAÜN Faculty Member Prof. Dr. Muradiye Nacak and Project Manager Prof. Dr. Aydın Erenmemişoğlu, taking all necessary protective measures in this critical period. Gaziantep University Technopark has made us proud as a solution partner of the National Pharmaceutical Industry and continues its efforts at full speed during these critical pandemic days."

Gaziantep University Rector Prof. Dr. Ali Gür further noted that there are several other drugs used in the treatment of COVID-19, for which bioequivalence studies are ongoing to enable local production in our country. He emphasized that once these legal approval processes are completed, they will be shared with the public. In his statement, he added, "We extend our gratitude to our academics, Technopark company, shared stakeholders, and everyone who contributed to these studies, which will make a significant contribution to the national pharmaceutical industry and the national economy during these critical pandemic days."